Squarepoint
PRLD icon

Squarepoint’s Prelude Therapeutics PRLD Stock Holding History

Squarepoint’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
+59,540
New +$259K ﹤0.01% 3768
2024
Q1 		– Sell
-29,418
Closed -$126K – 4482
2023
Q4 		$126K Sell
29,418
-59,384
-67% -$181K ﹤0.01% 3710
2023
Q3 		$274K Buy
88,802
+69,675
+364% +$261K ﹤0.01% 3226
2023
Q2 		$86.1K Buy
+19,127
New +$114K ﹤0.01% 3385
2022
Q3 		– Sell
-19,618
Closed -$102K – 3340
2022
Q2 		$102K Sell
19,618
-11,716
-37% -$59.6K ﹤0.01% 2616
2022
Q1 		$216K Sell
31,334
-17,333
-36% -$159K ﹤0.01% 2441
2021
Q4 		$606K Buy
+48,667
New +$792K ﹤0.01% 2019
2021
Q1 		– Sell
-20,726
Closed -$1.48M – 3512
2020
Q4 		$1.48M Sell
20,726
-33,340
-62% -$1.66M 0.01% 1097
2020
Q3 		$1.63M Buy
+54,066
New +$1.53M 0.02% 745

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Squarepoint's PRLD Position: Q2 2026 in Review

Squarepoint opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 59,540 shares worth $317K. The stake represents ﹤0.01% of the portfolio and ranks #3768 among its holdings. This is a return to the name: Squarepoint previously reported a position in PRLD as recently as Q4 2023.

Squarepoint first reported a position in PRLD in Q3 2020 and has held it in 9 quarters since. The position peaked at $1.63M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Squarepoint held 59,540 shares of Prelude Therapeutics worth $317K as of Q2 2026.
  • Prelude Therapeutics was a new Squarepoint position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3768 holding.
  • Squarepoint first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 9 quarters since.
  • Squarepoint's Prelude Therapeutics position peaked at $1.63M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.